middle.news
PYC Therapeutics Launches First Human Trials for Groundbreaking PKD Therapy
8:51am on Monday 10th of February, 2025 AEDT
•
Biotechnology
Read Story
PYC Therapeutics Launches First Human Trials for Groundbreaking PKD Therapy
8:51am on Monday 10th of February, 2025 AEDT
Key Points
Regulatory approval granted for PYC-003 human trials in PKD
Single Ascending Dose study to assess safety and efficacy in healthy volunteers and PKD patients
Initial clinical data anticipated within 2025
PKD affects approximately 1 in 1,000 people globally with limited treatment options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE